ABCC7 p.Arg766Met
ClinVar: |
c.2297G>T
,
p.Arg766Met
?
, not provided
|
CF databases: |
c.2297G>T
,
p.Arg766Met
(CFTR1)
D
, R766M was identified by non-radioactive SSCP and direct sequencing; it creates a FokI restriction site.
|
Predicted by SNAP2: | A: D (85%), C: D (91%), D: D (95%), E: D (91%), F: D (91%), G: D (91%), H: D (91%), I: D (91%), K: D (75%), L: D (91%), M: D (66%), N: D (91%), P: D (91%), Q: D (85%), S: D (85%), T: D (85%), V: D (85%), W: D (95%), Y: D (91%), |
Predicted by PROVEAN: | A: N, C: D, D: D, E: N, F: D, G: D, H: N, I: D, K: N, L: D, M: D, N: N, P: D, Q: N, S: N, T: D, V: D, W: D, Y: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] Two novel missense mutations (R766M and R792G) in ... Hum Hered. 2000 Sep-Oct;50(5):318-9. Ravnik-Glavac M, Dean M, Glavac D
Two novel missense mutations (R766M and R792G) in exon 13 of the CFTR gene in a patient with congenital bilateral absence of the vas deferens.
Hum Hered. 2000 Sep-Oct;50(5):318-9., [PMID:10878476]
Abstract [show]
Comments [show]
None has been submitted yet.
No. Sentence Comment
2 One is a substitution of thymine for guanine at nucleotide position 2429, which causes at amino acid level a substitution of methionine (R766M) for arginine at 766.
X
ABCC7 p.Arg766Met 10878476:2:137
status: NEW21 No normal single-stranded DNAs (alleles) have been detected in sample 3 carrying mutations R766M and R792G.
X
ABCC7 p.Arg766Met 10878476:21:91
status: NEW24 It is very likely that the newly detected genotype R766M/R792G in a CBAVD patient is connected with a disease phenotype.
X
ABCC7 p.Arg766Met 10878476:24:51
status: NEW29 Frequency Both R766M and R792G have each been detected once in 84 CBAVD chromosomes and have not been found in 230 normal chromosomes tested in this study.
X
ABCC7 p.Arg766Met 10878476:29:15
status: NEW30 Other Comments Single-strand conformational polymorphism (SSCP) analysis showed that R766M and R792G are present on different CFTR alleles of a CBAVD patient.
X
ABCC7 p.Arg766Met 10878476:30:85
status: NEW[hide] CFTR regulatory region interacts with NBD1 predomi... Nat Struct Mol Biol. 2007 Aug;14(8):738-45. Epub 2007 Jul 29. Baker JM, Hudson RP, Kanelis V, Choy WY, Thibodeau PH, Thomas PJ, Forman-Kay JD
CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices.
Nat Struct Mol Biol. 2007 Aug;14(8):738-45. Epub 2007 Jul 29., [PMID:17660831]
Abstract [show]
The regulatory (R) region of the cystic fibrosis transmembrane conductance regulator (CFTR) is intrinsically disordered and must be phosphorylated at multiple sites for full CFTR channel activity, with no one specific phosphorylation site required. In addition, nucleotide binding and hydrolysis at the nucleotide-binding domains (NBDs) of CFTR are required for channel gating. We report NMR studies in the absence and presence of NBD1 that provide structural details for the isolated R region and its interaction with NBD1 at residue-level resolution. Several sites in the R region with measured fractional helical propensity mediate interactions with NBD1. Phosphorylation reduces the helicity of many R-region sites and reduces their NBD1 interactions. This evidence for a dynamic complex with NBD1 that transiently engages different sites of the R region suggests a structural explanation for the dependence of CFTR activity on multiple PKA phosphorylation sites.
Comments [show]
None has been submitted yet.
No. Sentence Comment
149 Milder phenotypes are seen for many cystic fibrosis-causing CFTR missense mutations within the R region, consistent with this multisite behavior, and the majority of these mutations are at the PKA recognition and phosphorylation sites (R709N, S712C, R735K, S737F, V754M, R766M, R810G and S813P; http://www.
X
ABCC7 p.Arg766Met 17660831:149:271
status: NEW[hide] Do common in silico tools predict the clinical con... Clin Genet. 2010 May;77(5):464-73. Epub 2009 Jan 6. Dorfman R, Nalpathamkalam T, Taylor C, Gonska T, Keenan K, Yuan XW, Corey M, Tsui LC, Zielenski J, Durie P
Do common in silico tools predict the clinical consequences of amino-acid substitutions in the CFTR gene?
Clin Genet. 2010 May;77(5):464-73. Epub 2009 Jan 6., [PMID:20059485]
Abstract [show]
Computational methods are used to predict the molecular consequences of amino-acid substitutions on the basis of evolutionary conservation or protein structure, but their utility in clinical diagnosis or prediction of disease outcome has not been well validated. We evaluated three popular computer programs, namely, PANTHER, SIFT and PolyPhen, by comparing the predicted clinical outcomes for a group of known CFTR missense mutations against the diagnosis of cystic fibrosis (CF) and clinical manifestations in cohorts of subjects with CF-disease and CFTR-related disorders carrying these mutations. Owing to poor specificity, none of tools reliably distinguished between individual mutations that confer CF disease from mutations found in subjects with a CFTR-related disorder or no disease. Prediction scores for CFTR mutations derived from PANTHER showed a significant overall statistical correlation with the spectrum of disease severity associated with mutations in the CFTR gene. In contrast, PolyPhen- and SIFT-derived scores only showed significant differences between CF-causing and non-CF variants. Current computational methods are not recommended for establishing or excluding a CF diagnosis, notably as a newborn screening strategy or in patients with equivocal test results.
Comments [show]
None has been submitted yet.
No. Sentence Comment
64 Mutations in the CFTR gene grouped by clinical category Cystic fibrosis CFTR-related disease No disease T338I D614G L320V V920L L90S M470V H199R S1251N I203M G550R P111A I148T Q1291H R560K L1388Q L183I R170H I1027T S549R D443Y P499A L1414S T908N R668C S549N A455E E1401K Q151K G27E I1234L Y563N R347P C866R S1118C P1290S R75Q A559T V520F P841R M469V E1401G P67L G85E S50Y E1409K R933G G458V G178R Y1032C R248T I980K G85V V392G L973P L137H T351S R334W I444S V938G R792G R560T R555G L1339F D1305E P574H V1240G T1053I D58G G551D L1335P I918M F994C S945L L558S F1337V R810G D1152H G1247R P574S R766M D579G W1098R H949R F200I R352Q L1077P K1351E M244K L206W M1101K D1154G L375F N1303K R1066C E528D D110Y R347H R1070Q A800G P1021S S549K A1364V V392A damaging` (is supposed to affect protein function or structure) and 'probably damaging` (high confidence of affecting protein function or structure).
X
ABCC7 p.Arg766Met 20059485:64:590
status: NEW[hide] Characterization of 19 disease-associated missense... Hum Mol Genet. 1998 Oct;7(11):1761-9. Vankeerberghen A, Wei L, Jaspers M, Cassiman JJ, Nilius B, Cuppens H
Characterization of 19 disease-associated missense mutations in the regulatory domain of the cystic fibrosis transmembrane conductance regulator.
Hum Mol Genet. 1998 Oct;7(11):1761-9., [PMID:9736778]
Abstract [show]
In order to gain a better insight into the structure and function of the regulatory domain (RD) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, 19 RD missense mutations that had been identified in patients were functionally characterized. Nine of these (I601F, L610S, A613T, D614G, I618T, L619S, H620P, G628R and L633P) resulted in aberrant processing. No or a very small number of functional CFTR proteins will therefore appear at the cell membrane in cells expressing these mutants. These mutations were clustered in the N-terminal part of the RD, suggesting that this subdomain has a folding pattern that is very sensitive to amino acid changes. Mutations that caused no aberrant processing were further characterized at the electrophysiological level. First, they were studied at the whole cell level in Xenopus laevis oocytes. Mutants that induced a whole cell current that was significantly different from wild-type CFTR were subsequently analysed at the single channel level in COS1 cells transiently expressing the different mutant and wild-type proteins. Three mutant chloride channels, G622D, R792G and E822K CFTR, were characterized by significantly lower intrinsic chloride channel activities compared with wild-type CFTR. Two mutations, H620Q and A800G, resulted in increased intrinsic chloride transport activities. Finally, T665S and E826K CFTR had single channel properties not significantly different from wild-type CFTR.
Comments [show]
None has been submitted yet.
No. Sentence Comment
42 Of the 21 RD missense mutations, three (K698R, R766M and R792G) were located in PKA recognition consensus sites.
X
ABCC7 p.Arg766Met 9736778:42:47
status: NEW43 Only R766M and R792G disrupted a PKA recognition site and might therefore interfere with CFTR regulation.
X
ABCC7 p.Arg766Met 9736778:43:5
status: NEW68 Primers used for mutagenesis Primer Sequence I601F (a1933t) 5'-CTA ACA AAA CTA GGT TTT TGG TCA CTT C-3' L610S (t1961c) 5'-CTA AAA TGG AAC ATT CAA AGA AAG CTG-3' A613T (g1969a) 5'-CAT TTA AAG AAA ACT GAC AAA ATA TTA-3' D614G (a1973g) 5'-CAT TTA AAG AAA GCT GGC AAA ATA TTA A-3' I618T (t1985c) 5'-GAC AAA ATA TTA ACT TTG CAT GAA GG-3' L619S (t1988c) 5'-GAC AAA ATA TTA ATT TCG CAT GAA GGT-3' H620P (a1991c) 5'-CAA AAT ATT AAT TTT GCC TGA AGG TAG C-3' H620Q (t1992g) 5'-AAT ATT AAT TTT GCA GGA AGG TAG CAG-3' G622D (g1997a) 5'-TTG CAT GAA GAT AGC AGC TAT TTT TAT G-3' G628R (g2014c) 5'-GCA GCT ATT TTT ATC GGA CAT TTT C-3' L633P (t2030c) 5'-CAT TTT CAG AAC CCC AAA ATC TAC AGC-3' D648V (a2075t) 5'-CTC ATG GGA TGT GTT TCT TTC GAC C-3' T665S (a2125t) 5'-CAA TCC TAA CTG AGT CCT TAC ACC G-3' F693L (t2209c) 5'-CAG ACT GGA GAG CTT GGG GAA AAA AG-3' R766M (g2429t) 5'-GCA CGA AGG ATG CAG TCT GTC CTG-3' R792G (c2506g) 5'-CAG CAT CCA CAG GAA AAG TGT CAC TG-3' A800G (c2531g) 5'-CTG GCC CCT CAG GGA AAC TTG ACT G-3' I807M (a2553g) 5'-CTG AAC TGG ATA TGT ATT CAA GAA GG-3' E822K (g2596a) 5'-GGC TTG GAA ATA AGT AAA GAA ATT AAC G-3' E826K (g2608a) 5'-GAA GAA ATT AAC AAA GAA GAC TTA AAG-3' Selection primer BstBI 5'-CTC TGG GGT CCG GAA TGA CCG AC-3' Two primers were used for each mutagenesis reaction.
X
ABCC7 p.Arg766Met 9736778:68:843
status: NEW77 Mutations detected in patients (I601F, L610S, A613T, D614G, I618T, L619S, H620P, H620Q, D622G, G628R, L633P, T665S, F693L, K698R, V754M, R766M, R792G, A800G, I807M, E822K and E826K) are indicated in bold and underlined, the PKA phosphorylation sites by an arrow and the two acidic domains are boxed.
X
ABCC7 p.Arg766Met 9736778:77:137
status: NEW85 The remainder (G622D, D648V, F693L, R766M and I807M) did not significantly affect chloride transport ability when compared with wild-type CFTR channels.
X
ABCC7 p.Arg766Met 9736778:85:36
status: NEW87 Maturation pattern of RD mutations and their associated phenotype found in patients with the indicated genotype (when the mutation is associated with CF, only the pancreas status is given) Mutation A-form B-form C-form Clinical data Genotype Phenotype Reference I601F + + - I601F/G542X PS M. Schwarz, personal communication L610S + + - Unknown Unknown A613T + + - Unknown Unknown D614G + + - D614G/unknown PI 14 I618T + + - I618T/dF508 PS G.R. Cutting, personal communication L619S + + - L619S/unknown PI B. Tümmler, personal communication H620P + + - H620P/R1158X PS M. Schwarz, personal communication H620Q + + + H620Q/dF508 PI T. Dörk, personal communication G622D + + + G622D/unknown Oligospermia J. Zielenski, personal communication G628R + + - Unknown Unknown L633P + + - L633P/3659delC M. Schwarz, personal communication D648V + + + D648V/3849+10kb C/T PI C. Ferec, personal communication T665S + + + Unknown Unknown F693L + + + F693L/W1282X Healthy C. Ferec; CF Genetic Analysis Consortium R766M + + + R766M/R792G CBAVD D. Glavac, personal communication R792G + + + R766M/R792G CBAVD D. Glavac, personal communication A800G + + + A800G/unknown CBAVD 34 I807M + + + I807M/unknown CBAVD Our observation E822K + + + E822K/unknown PI 35 E826K + + + E826K/unknown Thoracic sarcoidosis C. Bombieri, personal communication +, the protein matures up to that form; -, the protein does not reach the respective maturation step.
X
ABCC7 p.Arg766Met 9736778:87:1008
status: NEWX
ABCC7 p.Arg766Met 9736778:87:1020
status: NEWX
ABCC7 p.Arg766Met 9736778:87:1084
status: NEW123 Mutations that did not affect maturation (H620Q, G622D, D648V, T665S, F693L, R766M, R792G, A800G, I807M, E822K and E826K) were subsequently analysedat theelectrophysiologi- cal level.
X
ABCC7 p.Arg766Met 9736778:123:77
status: NEW131 The remaining mutations (D648V, T665S, F693L, R766M, I807M and E826K) caused no significant alterations in intrinsic chloride channel activity.
X
ABCC7 p.Arg766Met 9736778:131:46
status: NEW[hide] Regulation of Activation and Processing of the Cys... J Biol Chem. 2012 Oct 11. Wang G, Duan DD
Regulation of Activation and Processing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) by a Complex Electrostatic Interaction between the Regulatory Domain and Cytoplasmic Loop 3.
J Biol Chem. 2012 Oct 11., [PMID:23060444]
Abstract [show]
NEG2, a short C-terminal segment (817-838) of the unique regulatory (R) domain of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel, has been reported to regulate CFTR gating in response to cAMP-dependent R domain phosphorylation. The underlying mechanism, however, is unclear. Here, K946 of cytoplasmic loop 3 (CL3) is proposed as counter-ion of D835, D836 or E838 of NEG2 to prevent channel activation by PKA. R764 or R766 of the S768 phosphorylation site of the R domain is proposed to promote channel activation possibly by weakening the putative CL3-NEG2 electrostatic attraction. First, not only D835A, D836A and E838A but also K946A reduced the PKA dependent CFTR activation. Second, both K946D and D835R/D836R/E838R mutants were activated by ATP and curcumin to a different extent. Third, R764A and R766A mutants enhanced the PKA-dependent activation. On the other hand, it is very exciting that D835R/D836R/E838R and K946D/H950D and H950R exhibited normal channel processing and activity while D835R/D836R/E838R/K946D/H950D was misprocessed and silent in response to forskolin. Further, D836R and E838R played a critical role in the asymmetric electrostatic regulation of CFTR processing and S768 phosphorylation may not be involved. Thus, a complex interfacial interaction among CL3, NEG2 and the S768 phosphorylation site may be responsible for the asymmetric electrostatic regulation of CFTR activation and processing.
Comments [show]
None has been submitted yet.
No. Sentence Comment
117 Because R764X and R766M were reported with CF patients (www.genet.sickkids.on.ca/cftr/app), we investigated if missense alanine mutation of R764 and R766 alters the channel processing and activity.
X
ABCC7 p.Arg766Met 23060444:117:18
status: NEW141 However, the putative electrostatic attraction between K946/H950R and D835/D836/E838 failed to exert this inhibitory effect (Fig.4-5).
X
ABCC7 p.Arg766Met 23060444:141:18
status: NEW[hide] A novel model for the first nucleotide binding dom... FEBS Lett. 1997 May 5;407(3):303-8. Annereau JP, Wulbrand U, Vankeerberghen A, Cuppens H, Bontems F, Tummler B, Cassiman JJ, Stoven V
A novel model for the first nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator.
FEBS Lett. 1997 May 5;407(3):303-8., [PMID:9175873]
Abstract [show]
Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The most frequent mutation is the deletion of F508 in the first nucleotide binding fold (NBF1). It induces a perturbation in the folding of NBF1, which impedes posttranslational maturation of CFTR. Determination of the three-dimensional structure of NBF1 would help to understand this defect. We present a novel model for NBF1 built from the crystal structure of bovine mitochondrial F1-ATPase protein. This model gives a reasonable interpretation of the effect of mutations on the maturation of the protein and, in agreement with the CD data, leads to reconsideration of the limits of NBF1 within CFTR.
Comments [show]
None has been submitted yet.
No. Sentence Comment
70 The maturation patterns of six mutant R domain proteins were determined (Fig. 3): CFTR-L610S, CFTR-G628R and CFTR-L633P matured to the core-glycosylated form, while CFTR-D648V, CFTR-T665S and CFTR-R766M matured to the complete glycosylated form.
X
ABCC7 p.Arg766Met 9175873:70:197
status: NEW134 COS cells transfected with wild-type CFTR-L610S and CFTR-R766M were metabolically labelled, chased and CFTR was immunoprecipitated and separated on a SDS-PAGE gel.
X
ABCC7 p.Arg766Met 9175873:134:57
status: NEW150 The mutations L610S (tc at 1961), G628R (gc at 2014), L633P (tc at 2030), D648V (at at 2075), T665S (at at 2125) and R766M (gt at 2429) (nucleotide and amino acid assignment according to [2]) were introduced using the Transformer Site-Directed Mutagenesis kit (Clontech, Heidelberg, Germany).
X
ABCC7 p.Arg766Met 9175873:150:117
status: NEW135 COS cells transfected with wild-type CFTR-L610S and CFTR-R766M were metabolically labelled, chased and CFTR was immunoprecipitated and separated on a SDS-PAGE gel.
X
ABCC7 p.Arg766Met 9175873:135:57
status: NEW151 The mutations L610S (tc at 1961), G628R (gc at 2014), L633P (tc at 2030), D648V (at at 2075), T665S (at at 2125) and R766M (gt at 2429) (nucleotide and amino acid assignment according to [2]) were introduced using the Transformer Site-Directed Mutagenesis kit (Clontech, Heidelberg, Germany).
X
ABCC7 p.Arg766Met 9175873:151:117
status: NEW[hide] Definition of a "functional R domain" of the cysti... Mol Genet Metab. 2000 Sep-Oct;71(1-2):245-9. Chen JM, Scotet V, Ferec C
Definition of a "functional R domain" of the cystic fibrosis transmembrane conductance regulator.
Mol Genet Metab. 2000 Sep-Oct;71(1-2):245-9., [PMID:11001817]
Abstract [show]
The R domain of the cystic fibrosis transmembrane conductance regulator (CFTR) was originally defined as 241 amino acids, encoded by exon 13. Such exon/intron boundaries provide a convenient way to define the R domain, but do not necessarily reflect the corresponding functional domain within CFTR. A two-domain model was later proposed based on a comparison of the R-domain sequences from 10 species. While RD1, the N-terminal third of the R domain is highly conserved, RD2, the large central region of the R domain has less rigid structural requirements. Although this two-domain model was given strong support by recent functional analysis data, the simple observation that two of the four main phosphorylation sites are excluded from RD2 clearly indicates that RD2 still does not satisfy the requirements of a "functional R domain." Nevertheless, knowledge of the CFTR structure and function accumulated over the past decade and reevaluated in the context of a comprehensive sequence comparison of 15 CFTR homologues made it possible to define such a "functional R domain," i.e., amino acids C647 to D836. This definition is validated primarily because it contains all of the important potential consensus phosphorylation sequences. In addition, it includes the highly charged motif from E822 to D836. Finally, it includes all of the deletions/insertions in this region. This definition also aids in understanding the effects of missense mutations occurring within this domain.
Comments [show]
None has been submitted yet.
No. Sentence Comment
62 The fact that R766M changes a most favorable phosphorylation sequence (R-R/K-X-S) to a less favorable one (R-X-X-S) suggests that even if R766M produces any effect, its effect must be minor and, in this regard, R766M did not show significant functional difference compared with wild-type CFTR (8).
X
ABCC7 p.Arg766Met 11001817:62:14
status: NEWX
ABCC7 p.Arg766Met 11001817:62:138
status: NEWX
ABCC7 p.Arg766Met 11001817:62:211
status: NEW